Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - ScienceDirect
Jeff Szer on X: "John Seymour from @Haem_pmcc_rmh presenting MURANO trial of time-limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). #ASH18 https://t.co/aCOdDI4yC2" / X
Vaso CARLO MORETTI Collezione "I piccoli" Vetro di MURANO Made in Italy Edizione Limitata ORION : Amazon.it: Casa e cucina
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL - The ASCO Post
CLL: The main clinical message from the Five-Year Analysis of Murano Study
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - ScienceDirect
Relapsed / Refractory CLL | Haematology | AbbVie UK
VENCLEXTA® (venetoclax tablets) | VEN+R Safety Data for CLL/SLL
Relapsed / Refractory CLL | Haematology | AbbVie UK
Relapsed / Refractory CLL | Haematology | AbbVie UK
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
5-year data show sustained benefit of venetoclax-rituximab for relapsed/refractory CLL
Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab | Haematologica
Lymphoma Hub on X: "Arnon Kater from @UvA_Amsterdam at #ASH18 presented the results from the phase III MURANO trial focusing on the impact of MRD on long-term clinical outcomes following treatment #CLL #
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy - ScienceDirect
Mednet - CME, CHE | A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed
Updated results from the phase III MURANO trial - BJH
MURANO Trial Update in R/R CLL
5-year results of the MURANO phase III trial of venetoclax + rituximab vs bendamustine + rituximab in patients with CLL
CLL, update dal follow-up a 7 anni dello studio MURANO
Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia
John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study
EHA 2023: MURANO-Langzeitergebnisse und Folgetherapien | congress-x-press
Journal of Clinical Oncology on X: "Four-year follow up of relapsed/refractory CLL in MURANO trial shows improved survival with venetoclax-rituximab compared to bendamustine-rituximab https://t.co/O6agxSZDcX #leusm #lymsm @PeterMacCC https://t.co ...
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
